Kinnate Biopharma Inc.
KNTENASDAQHealthcare
$2.65
$-0.01(-0.38%)
Market Cap$124990960
P/E Ratio—
52W High$7.185
52W Low$1.04
Kinnate Biopharma Inc.（KNTE）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · KNTE · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.09B | $0.09B | $0.07B | $0.03B | $0.01B |
| G&A Expenses | $0.00B | $0.03B | $0.02B | $0.01B | $0.00B |
| Total Operating Expenses | $0.12B | $0.12B | $0.09B | $0.04B | $0.01B |
| Operating Income | ($0.12B) | ($0.12B) | ($0.09B) | ($0.04B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.11B) | ($0.12B) | ($0.09B) | ($0.04B) | ($0.01B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | ($0.00B) |
| Net Income | ($0.11B) | ($0.11B) | ($0.09B) | ($0.04B) | ($0.01B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.42 | $-2.59 | $-2.05 | $-0.81 | $-0.28 |
| Wtd Avg Shares | 0.05B | 0.04B | 0.04B | 0.04B | 0.04B |
| EBITDA | ($0.12B) | ($0.12B) | ($0.09B) | ($0.04B) | ($0.01B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · B
深入了解Kinnate Biopharma Inc.
关于Kinnate Biopharma Inc.（KNTE）损益表
Kinnate Biopharma Inc.（KNTE）损益表数据来源于SEC Form 10-K及10-Q申报文件。2023财年，KNTE实现营收$0.00B，毛利润($0.00B)（毛利率—），净利润($0.11B)（净利率—）。
常见问题
KNTE · 4 问Kinnate Biopharma Inc.（KNTE）2023财年营收为$0.00B，同比down—%。
KNTE revenueKNTE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09